NEW YORK (360Dx) – While known primarily as a blood plasma-based products firm, Grifols has progressively built up its diagnostics business. Now, those investments are showing up in both the firm's top and bottom lines.
On Friday, the company reported revenues in its diagnostics division rose by 11 percent during the first half of 2017 to €351.1 million ($410.8 million), compared to €316.8 in the first half of 2016. For the second quarter of 2017, diagnostic sales were up 16 percent year over year, the firm said.